Published in Regul Pept on February 15, 2005
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation (2011) 2.52
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol (2009) 1.41
Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab (2009) 1.38
The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol (2012) 1.32
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc (2013) 1.24
Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes (2008) 1.24
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Rev Diabet Stud (2008) 1.19
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol (2010) 1.17
The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther (2010) 1.12
Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol (2008) 1.00
Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care (2012) 0.99
Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol (2012) 0.99
Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1. Cardiovasc Diabetol (2014) 0.94
Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS One (2012) 0.93
Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection. Cardiovasc Diabetol (2013) 0.89
Cardiovascular effects of incretin-based therapies. Rev Diabet Stud (2011) 0.88
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Ther (2015) 0.88
Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats. Br J Pharmacol (2008) 0.87
Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production. Cardiovasc Diabetol (2014) 0.86
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists. Rev Diabet Stud (2009) 0.85
Hypoglycemia, hyperglucagonemia, and fetoplacental defects in glucagon receptor knockout mice: a role for glucagon action in pregnancy maintenance. Am J Physiol Endocrinol Metab (2011) 0.85
Effects of nitric oxide synthase inhibition with or without cyclooxygenase-2 inhibition on resting haemodynamics and responses to exendin-4. Br J Pharmacol (2006) 0.84
Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med (2008) 0.84
GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin Sci (Lond) (2014) 0.83
Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow. Exp Biol Med (Maywood) (2012) 0.83
The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol (2013) 0.83
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag (2006) 0.83
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2013) 0.83
Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis (2014) 0.82
Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm. J Am Heart Assoc (2014) 0.82
GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. Am J Physiol Endocrinol Metab (2013) 0.82
The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice. Exp Diabetes Res (2012) 0.81
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. Diabetes Metab Syndr Obes (2010) 0.81
Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Ther Clin Risk Manag (2010) 0.80
Direct cardiovascular effects of glucagon like peptide-1. Diabetol Metab Syndr (2013) 0.80
Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol (2014) 0.80
Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats. Cardiovasc Diabetol (2015) 0.79
Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Rev Endocr Metab Disord (2014) 0.78
Polymer-based delivery of glucagon-like Peptide-1 for the treatment of diabetes. ISRN Endocrinol (2012) 0.78
A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes. Diabetes Ther (2012) 0.78
GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring) (2015) 0.78
Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? Diabetes Ther (2016) 0.77
Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering. Hippokratia (2012) 0.77
Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetol Metab Syndr (2016) 0.77
Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance. J Physiol (2015) 0.77
GLP-1 (7-36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles. Cardiovasc Diabetol (2014) 0.76
Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure. Int J Mol Sci (2015) 0.76
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists. Endocrinol Metab (Seoul) (2016) 0.76
Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Ther Adv Drug Saf (2012) 0.76
The effect of gum chewing on blood GLP-1 concentration in fasted, healthy, non-obese men. Endocrine (2015) 0.75
Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure. Diabetol Metab Syndr (2016) 0.75
Blood pressure and cardiovascular effects of new and emerging antidiabetic agents. Curr Hypertens Rep (2014) 0.75
Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure. Am J Transl Res (2016) 0.75
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab (2004) 3.65
Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature (2012) 2.83
Remote ischaemic pre- and delayed postconditioning - similar degree of cardioprotection but distinct mechanisms. Exp Physiol (2012) 1.80
The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res (2007) 1.74
Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J (2008) 1.65
Identification and predictive value of interleukin-6+ interleukin-10+ and interleukin-6- interleukin-10+ cytokine patterns in ST-elevation acute myocardial infarction. Circ Res (2012) 1.55
Endothelin-A receptor blockade increases nutritive skin capillary circulation in patients with type 2 diabetes and microangiopathy. J Vasc Res (2008) 1.53
Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res (2010) 1.27
Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide. Cardiovasc Res (2008) 1.24
Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res (2002) 1.23
Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol (2002) 1.19
PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway. Am J Physiol Heart Circ Physiol (2009) 1.19
Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation (2012) 1.14
Assessment of myocardium at risk with contrast enhanced steady-state free precession cine cardiovascular magnetic resonance compared to single-photon emission computed tomography. J Cardiovasc Magn Reson (2010) 1.07
Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol Heart Circ Physiol (2011) 1.06
Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart (2010) 1.04
Local arginase inhibition during early reperfusion mediates cardioprotection via increased nitric oxide production. PLoS One (2012) 1.01
Ethanol acutely stimulates islet blood flow, amplifies insulin secretion, and induces hypoglycemia via nitric oxide and vagally mediated mechanisms. Endocrinology (2007) 0.99
Arginase regulates red blood cell nitric oxide synthase and export of cardioprotective nitric oxide bioactivity. Proc Natl Acad Sci U S A (2013) 0.98
Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction. Atherosclerosis (2011) 0.98
Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol (2013) 0.97
Different subpopulations of endothelial progenitor cells and circulating apoptotic progenitor cells in patients with vascular disease and diabetes. Int J Cardiol (2009) 0.97
Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis. Arterioscler Thromb Vasc Biol (2002) 0.94
Diet supplementation with green tea extract epigallocatechin gallate prevents progression to glucose intolerance in db/db mice. Nutr Metab (Lond) (2012) 0.93
Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J Gastroenterol (2012) 0.93
Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res Cardiol (2006) 0.92
Dual endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care (2007) 0.92
Early signs of atherosclerosis are associated with insulin resistance in non-obese adolescent and young adults with type 1 diabetes. Cardiovasc Diabetol (2012) 0.91
Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin Sci (Lond) (2002) 0.90
A busy cell--endoplasmic reticulum stress in the pancreatic beta-cell. Mol Cell Endocrinol (2007) 0.90
Enhanced endothelium-dependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance. J Cardiovasc Pharmacol (2006) 0.89
Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept (2009) 0.89
Vitamin C blocks vascular dysfunction and release of interleukin-6 induced by endothelin-1 in humans in vivo. Atherosclerosis (2006) 0.88
Myocardium at risk by magnetic resonance imaging: head-to-head comparison of T2-weighted imaging and contrast-enhanced steady-state free precession. Eur Heart J Cardiovasc Imaging (2012) 0.88
ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) (2003) 0.88
Arginase inhibition reduces infarct size via nitric oxide, protein kinase C epsilon and mitochondrial ATP-dependent K+ channels. Eur J Pharmacol (2013) 0.88
Persistent endothelial dysfunction is related to elevated C-reactive protein (CRP) levels in Type II diabetic patients after acute myocardial infarction. Clin Sci (Lond) (2005) 0.88
Cardioprotective effect induced by brief exposure to nitric oxide before myocardial ischemia-reperfusion in vivo. Nitric Oxide (2002) 0.88
Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats. Clin Sci (Lond) (2007) 0.87
Association of waist circumference, traditional cardiovascular risk factors, and stromal-derived factor-1 in adolescents. Pediatr Diabetes (2008) 0.87
Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome. Diabetol Metab Syndr (2014) 0.86
Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity. Diabetes Metab Res Rev (2009) 0.86
Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. Am J Physiol Endocrinol Metab (2004) 0.86
Endothelin-1 reduces glucose uptake in human skeletal muscle in vivo and in vitro. Diabetes (2011) 0.85
Nitric oxide mediates protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol (2003) 0.85
Opioid receptor agonist Eribis peptide 94 reduces infarct size in different porcine models for myocardial ischaemia and reperfusion. Eur J Pharmacol (2010) 0.85
Increased levels of tumour necrosis factor-alpha (TNF-alpha) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction. Clin Sci (Lond) (2006) 0.85
Involvement of JAK2 and Src kinase tyrosine phosphorylation in human growth hormone-stimulated increases in cytosolic free Ca2+ and insulin secretion. Am J Physiol Cell Physiol (2006) 0.84
BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner. Am J Physiol Cell Physiol (2008) 0.84
Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells. Biochem Biophys Res Commun (2012) 0.84
Regulation of glucose uptake by endothelin-1 in human skeletal muscle in vivo and in vitro. J Clin Endocrinol Metab (2010) 0.83
Pituitary adenylate cyclase-activating polypeptide counteracts the impaired adult neural stem cell viability induced by palmitate. J Neurosci Res (2011) 0.83
Global expression profiling of glucose-regulated genes in pancreatic islets of spontaneously diabetic Goto-Kakizaki rats. J Mol Endocrinol (2007) 0.83
Thapsigargin down-regulates protein levels of GRP78/BiP in INS-1E cells. J Cell Biochem (2012) 0.82
Ljungan virus present in intrauterine fetal death diagnosed by both immunohistochemistry and PCR. Birth Defects Res A Clin Mol Teratol (2009) 0.82
C-peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism. Am J Physiol Endocrinol Metab (2003) 0.82
Intrauterine death, fetal malformation, and delayed pregnancy in Ljungan virus-infected mice. Birth Defects Res B Dev Reprod Toxicol (2006) 0.82
Early microvascular dysfunction in healthy normal-weight males with heredity for type 2 diabetes. Diabetes Care (2005) 0.81
Hypoxia followed by re-oxygenation induces oxidation of tyrosine phosphatases. Cell Signal (2011) 0.81
Increased arginase levels in heart failure represent a therapeutic target to rescue microvascular perfusion. Clin Hemorheol Microcirc (2013) 0.81
The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans. Clin Sci (Lond) (2005) 0.81
Arginase as a target for treatment of myocardial ischemia-reperfusion injury. Eur J Pharmacol (2013) 0.81
An automatic method for quantification of myocardium at risk from myocardial perfusion SPECT in patients with acute coronary occlusion. J Nucl Cardiol (2010) 0.80
Calcium antagonist clevidipine reduces myocardial reperfusion injury by a mechanism related to bradykinin and nitric oxide. J Cardiovasc Pharmacol (2002) 0.80
Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation. Am J Physiol Heart Circ Physiol (2007) 0.80
Fetal death persists through recurrent pregnancies in mice following Ljungan virus infection. Birth Defects Res B Dev Reprod Toxicol (2008) 0.80
Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats. Regul Pept (2012) 0.80
Pioglitazone acutely influences glucose-sensitive insulin secretion in normal and diabetic human islets. Biochem Biophys Res Commun (2006) 0.80
Improved peripheral perfusion during endothelin--a receptor blockade in patients with type 2 diabetes and critical limb ischemia. Diabetes Care (2008) 0.79
Human cytomegalovirus induces upregulation of arginase II: possible implications for vasculopathies. Basic Res Cardiol (2014) 0.79
GalR3 activation promotes adult neural stem cell survival in response to a diabetic milieu. J Neurochem (2013) 0.79
Pancreatic islet blood flow is selectively enhanced by captopril, irbesartan and pravastatin, and suppressed by palmitate. Biochem Biophys Res Commun (2006) 0.79
Glutamate inhibits protein phosphatases and promotes insulin exocytosis in pancreatic beta-cells. Biochem Biophys Res Commun (2005) 0.79
Intracoronary endothelin receptor blockade improves endothelial function in patients with coronary artery disease. Can J Physiol Pharmacol (2008) 0.79
No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance. Thromb Haemost (2009) 0.79
Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers. J Hypertens (2009) 0.78
Increased levels of circulating arginase I in overweight compared to normal weight adolescents. Pediatr Diabetes (2013) 0.78
Effects of spontaneous or induced brain ischemia on vessel reactivity: the role of inducible nitric oxide synthase. Life Sci (2002) 0.78
The specific VPAC2 agonist Bay 55-9837 increases neuronal damage and hemorrhagic transformation after stroke in type 2 diabetic rats. Neuropeptides (2012) 0.78
Endothelin-1 exerts a preconditioning-like cardioprotective effect against ischaemia/reperfusion injury via the ET(A) receptor and the mitochondrial K(ATP) channel in the rat in vivo. Br J Pharmacol (2005) 0.78
Long-term impact of postconditioning on infarct size and left ventricular ejection fraction in patients with ST-elevation myocardial infarction. BMC Cardiovasc Disord (2013) 0.78
Differential effects of metoprolol and atenolol to neuropeptide Y blockade in coronary artery disease. Scand Cardiovasc J (2011) 0.78
Increased arginase levels contribute to impaired perfusion after cardiopulmonary resuscitation. Eur J Clin Invest (2014) 0.77
Effects of myocardial postconditioning on the recruitment of endothelial progenitor cells. J Interv Cardiol (2012) 0.77
Endothelial progenitor cells in relation to endothelin-1 and endothelin receptor blockade: a randomized, controlled trial. Int J Cardiol (2012) 0.77
Growth hormone signaling in pancreatic beta-cells--calcium handling regulated by growth hormone. Mol Cell Endocrinol (2008) 0.77
Myocardial protection by co-administration of L-arginine and tetrahydrobiopterin during ischemia and reperfusion. Int J Cardiol (2013) 0.76
Evidence for paracrine/autocrine regulation of GLP-1-producing cells. Am J Physiol Cell Physiol (2013) 0.76
Inhibition of palmitate-induced GADD34 expression augments apoptosis in mouse insulinoma cells (MIN6). Cell Biochem Funct (2014) 0.76
Enhanced vasoconstrictor effect of big endothelin-1 in patients with atherosclerosis: relation to conversion to endothelin-1. Atherosclerosis (2002) 0.76
Estimating cardiovascular disease risk in diabetes. Lancet (2006) 0.75
Inositol hexakisphosphate and sulfonylureas regulate beta-cell protein phosphatases. Biochem Biophys Res Commun (2004) 0.75
Cardioprotective effect of an endothelin receptor antagonist during ischaemia/reperfusion in the severely atherosclerotic mouse heart. Br J Pharmacol (2005) 0.75